Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Sanofi : France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/16/2018 | 08:44am CEST
FILE PHOTO:French multinational pharmaceutical company SANOFI logo is seen at the headquarters in Paris

PARIS (Reuters) - French healthcare and drugs group Sanofi has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday.

PARIS (Reuters) - French healthcare and drugs group Sanofi has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday.

Sanofi said the sale formed part of its strategy to focus on its main businesses in areas such as allergy treatments and nutritional products, and to simplify its business portfolio.

Private equity and investment firm Charterhouse Capital said the acquisition would help build up the healthcare portfolio of Cooper-Vemedia, which is a European drug manufacturer and distributor.

(Reporting by Sudip Kar-Gupta; Editing by Edmund Blair)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
04/21SANOFI AVENTIS PAKISTAN : Board of directors meeting of Sanofi - Aventis Pakista..
AQ
04/20Generics group Alvogen puts Eastern European operations up for sale - sources
RE
04/20SANOFI : Advent International enters into exclusive negotiations to acquire Zent..
AQ
04/19UN HEALTH AGENCY : Dengue vaccine shouldn't be used widely
AQ
04/19SANOFI : Advent, near deal to buy Sanofi`s Zentiva, lays out big goals for gener..
AQ
04/19SANOFI : Advent International to acquire Zentiva, Sanofi`s European generics bus..
AQ
04/18SANOFI : in talks with Advent to sell its European generics arm for 1.9bn
AQ
04/18SANOFI : CFO Jerome Contamine to Depart Later This Year
DJ
04/18SANOFI : in talks with Advent to sell its European generics unit for €1.9bn
AQ
04/17SANOFI : CFO Contamine to retire later this year
RE
More news
News from SeekingAlpha
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
04/20Now See Wall Street's 38 'Safer' International Dividend WallStars For April 
04/18ASLAN Pharmaceuticals Updates U.S. IPO Plans 
04/18Catalyst Pipeline Portfolio Updates - Strong Start To For The Portfolio 
04/17Evelo Biosciences Files For U.S. IPO 
Financials (€)
Sales 2018 35 107 M
EBIT 2018 8 633 M
Net income 2018 4 940 M
Debt 2018 14 433 M
Yield 2018 4,71%
P/E ratio 2018 16,06
P/E ratio 2019 14,21
EV / Sales 2018 2,75x
EV / Sales 2019 2,58x
Capitalization 81 998 M
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 79,1 €
Spread / Average Target 21%
EPS Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & Executive VP-Finance
Elias A. Zerhouni President-Global Research & Development
Ameet Nathwani Executive Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-9.14%100 746
JOHNSON & JOHNSON-8.71%339 783
PFIZER0.86%217 897
NOVARTIS-7.67%204 972
ROCHE HOLDING LTD.-12.52%191 890
MERCK AND COMPANY4.55%158 571